HEADER TRANSFERASE 04-JAN-07 2OFV TITLE CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LCK KINASE DOMAIN, RESIDUES 231-497; COMPND 5 SYNONYM: P56-LCK, LYMPHOCYTE CELL-SPECIFIC PROTEIN- COMPND 6 TYROSINE KINASE, LSK, T CELL- SPECIFIC PROTEIN-TYROSINE COMPND 7 KINASE; COMPND 8 EC: 2.7.10.2; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: LCK; SOURCE 6 EXPRESSION_SYSTEM: INSECT CELL; SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS LCK, KINASE DOMAIN, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR X.HUANG REVDAT 2 24-FEB-09 2OFV 1 VERSN REVDAT 1 27-FEB-07 2OFV 0 JRNL AUTH E.F.DIMAURO,J.NEWCOMB,J.J.NUNES,J.E.BEMIS, JRNL AUTH 2 C.BOUCHER,J.L.BUCHANAN,W.H.BUCKNER,V.J.CEE,L.CHAI, JRNL AUTH 3 H.L.DEAK,L.F.EPSTEIN,T.FAUST,P.GALLANT, JRNL AUTH 4 S.D.GEUNS-MEYER,A.GORE,Y.GU,B.HENKLE,B.L.HODOUS, JRNL AUTH 5 F.HSIEH,X.HUANG,J.L.KIM,J.H.LEE,M.W.MARTIN, JRNL AUTH 6 C.E.MASSE,D.C.MCGOWAN,D.METZ,D.MOHN, JRNL AUTH 7 K.A.MORGENSTERN,A.OLIVEIRA-DOS-SANTOS,V.F.PATEL, JRNL AUTH 8 D.POWERS,P.E.ROSE,S.SCHNEIDER,S.A.TOMLINSON, JRNL AUTH 9 Y.-Y.TUDOR,S.M.TURCI,A.A.WELCHER,R.D.WHITE,H.ZHAO, JRNL AUTH10 L.ZHU,X.ZHU JRNL TITL DISCOVERY OF AMINOQUINAZOLINES AS POTENT, ORALLY JRNL TITL 2 BIOAVAILABLE INHIBITORS OF LCK: SYNTHESIS, SAR, JRNL TITL 3 AND IN VIVO ANTI-INFLAMMATORY ACTIVITY JRNL REF J.MED.CHEM. V. 49 5671 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16970394 JRNL DOI 10.1021/JM0605482 REMARK 1 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 41284 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.274 REMARK 3 FREE R VALUE : 0.301 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3878 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 62 REMARK 3 SOLVENT ATOMS : 271 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.46 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2OFV COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 11-JAN-07. REMARK 100 THE RCSB ID CODE IS RCSB041083. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 41290 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 89.1 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.09100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 55.4 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.28100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1QPC REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.56 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.71 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.3 M MGACETATE, 5-12.5% PEG8000, REMARK 280 PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 71.33000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 33.44500 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 71.33000 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 33.44500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE BIOLOGICAL ASSEMBLY IS A MONOMER. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 THR A 226 REMARK 465 GLN A 227 REMARK 465 LYS A 228 REMARK 465 PRO A 229 REMARK 465 GLN A 230 REMARK 465 SER A 279 REMARK 465 MET A 280 REMARK 465 SER A 281 REMARK 465 PRO A 282 REMARK 465 ASP A 283 REMARK 465 ALA A 284 REMARK 465 PHE A 285 REMARK 465 ARG A 387 REMARK 465 LEU A 388 REMARK 465 ILE A 389 REMARK 465 GLU A 390 REMARK 465 ASP A 391 REMARK 465 ASN A 392 REMARK 465 GLU A 393 REMARK 465 TYR A 394 REMARK 465 THR A 395 REMARK 465 ALA A 396 REMARK 465 ARG A 397 REMARK 465 GLU A 398 REMARK 465 GLY A 399 REMARK 465 ALA A 400 REMARK 465 LYS A 401 REMARK 465 PHE A 402 REMARK 465 PRO A 403 REMARK 465 THR A 499 REMARK 465 ALA A 500 REMARK 465 THR A 501 REMARK 465 GLU A 502 REMARK 465 THR B 226 REMARK 465 GLN B 227 REMARK 465 LYS B 228 REMARK 465 PRO B 229 REMARK 465 GLN B 230 REMARK 465 LYS B 231 REMARK 465 SER B 279 REMARK 465 MET B 280 REMARK 465 SER B 281 REMARK 465 PRO B 282 REMARK 465 ASP B 283 REMARK 465 ASN B 392 REMARK 465 GLU B 393 REMARK 465 TYR B 394 REMARK 465 THR B 395 REMARK 465 ALA B 396 REMARK 465 ARG B 397 REMARK 465 GLU B 398 REMARK 465 GLY B 399 REMARK 465 ALA B 400 REMARK 465 LYS B 401 REMARK 465 PHE B 402 REMARK 465 GLY B 443 REMARK 465 MET B 444 REMARK 465 THR B 445 REMARK 465 ASN B 446 REMARK 465 PRO B 447 REMARK 465 GLU B 448 REMARK 465 VAL B 449 REMARK 465 ARG B 455 REMARK 465 ALA B 500 REMARK 465 THR B 501 REMARK 465 GLU B 502 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS(M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 231 CG CD CE NZ REMARK 470 GLN A 277 CG CD OE1 NE2 REMARK 470 LEU A 286 CG CD1 CD2 REMARK 470 THR A 308 OG1 CG2 REMARK 470 GLN A 309 CG CD OE1 NE2 REMARK 470 ASP A 374 CG OD1 OD2 REMARK 470 ILE A 404 CG1 CG2 CD1 REMARK 470 ILE A 450 CG1 CG2 CD1 REMARK 470 GLU A 454 CG CD OE1 OE2 REMARK 470 LYS B 276 CG CD CE NZ REMARK 470 GLN B 277 CG CD OE1 NE2 REMARK 470 PHE B 285 CG CD1 CD2 CE1 CE2 CZ REMARK 470 GLN B 298 CG CD OE1 NE2 REMARK 470 GLN B 309 CG CD OE1 NE2 REMARK 470 LYS B 335 CG CD CE NZ REMARK 470 ASP B 374 CG OD1 OD2 REMARK 470 LEU B 376 CG CD1 CD2 REMARK 470 GLU B 390 CG CD OE1 OE2 REMARK 470 ASP B 391 CG OD1 OD2 REMARK 470 PRO B 403 CG CD REMARK 470 ILE B 404 CG1 CG2 CD1 REMARK 470 LYS B 405 CG CD CE NZ REMARK 470 HIS B 436 CG ND1 CD2 CE1 NE2 REMARK 470 ILE B 450 CG1 CG2 CD1 REMARK 470 ARG B 461 CG CD NE CZ NH1 NH2 REMARK 470 ASP B 463 CG OD1 OD2 REMARK 470 GLU B 468 CG CD OE1 OE2 REMARK 470 LEU B 472 CG CD1 CD2 REMARK 470 LYS B 478 CG CD CE NZ REMARK 470 ARG B 491 CG CD NE CZ NH1 NH2 REMARK 470 THR B 499 OG1 CG2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LYS B 335 N - CA - C ANGL. DEV. = -17.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 363 -17.57 81.39 REMARK 500 ASP A 364 47.95 -141.72 REMARK 500 PHE A 383 29.24 -146.70 REMARK 500 LEU A 385 16.66 54.91 REMARK 500 ASN A 464 2.99 80.08 REMARK 500 TRP B 238 4.24 -152.54 REMARK 500 THR B 330 150.74 -49.00 REMARK 500 ILE B 334 7.63 55.53 REMARK 500 ILE B 338 -38.22 -32.42 REMARK 500 ARG B 363 -17.06 73.02 REMARK 500 SER B 373 -173.73 -65.59 REMARK 500 ASP B 382 105.80 -160.36 REMARK 500 PHE B 383 28.72 -148.26 REMARK 500 ASN B 464 -1.07 105.35 REMARK 500 TRP B 477 36.17 -91.48 REMARK 500 ASP B 496 38.13 -70.98 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 242 A 503 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 242 B 503 DBREF 2OFV A 226 502 UNP P06239 LCK_HUMAN 226 502 DBREF 2OFV B 226 502 UNP P06239 LCK_HUMAN 226 502 SEQADV 2OFV THR A 226 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLN A 227 UNP P06239 CLONING ARTIFACT SEQADV 2OFV LYS A 228 UNP P06239 CLONING ARTIFACT SEQADV 2OFV PRO A 229 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLN A 230 UNP P06239 CLONING ARTIFACT SEQADV 2OFV LYS A 231 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR A 499 UNP P06239 CLONING ARTIFACT SEQADV 2OFV ALA A 500 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR A 501 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLU A 502 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR B 226 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLN B 227 UNP P06239 CLONING ARTIFACT SEQADV 2OFV LYS B 228 UNP P06239 CLONING ARTIFACT SEQADV 2OFV PRO B 229 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLN B 230 UNP P06239 CLONING ARTIFACT SEQADV 2OFV LYS B 231 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR B 499 UNP P06239 CLONING ARTIFACT SEQADV 2OFV ALA B 500 UNP P06239 CLONING ARTIFACT SEQADV 2OFV THR B 501 UNP P06239 CLONING ARTIFACT SEQADV 2OFV GLU B 502 UNP P06239 CLONING ARTIFACT SEQRES 1 A 277 THR GLN LYS PRO GLN LYS PRO TRP TRP GLU ASP GLU TRP SEQRES 2 A 277 GLU VAL PRO ARG GLU THR LEU LYS LEU VAL GLU ARG LEU SEQRES 3 A 277 GLY ALA GLY GLN PHE GLY GLU VAL TRP MET GLY TYR TYR SEQRES 4 A 277 ASN GLY HIS THR LYS VAL ALA VAL LYS SER LEU LYS GLN SEQRES 5 A 277 GLY SER MET SER PRO ASP ALA PHE LEU ALA GLU ALA ASN SEQRES 6 A 277 LEU MET LYS GLN LEU GLN HIS GLN ARG LEU VAL ARG LEU SEQRES 7 A 277 TYR ALA VAL VAL THR GLN GLU PRO ILE TYR ILE ILE THR SEQRES 8 A 277 GLU TYR MET GLU ASN GLY SER LEU VAL ASP PHE LEU LYS SEQRES 9 A 277 THR PRO SER GLY ILE LYS LEU THR ILE ASN LYS LEU LEU SEQRES 10 A 277 ASP MET ALA ALA GLN ILE ALA GLU GLY MET ALA PHE ILE SEQRES 11 A 277 GLU GLU ARG ASN TYR ILE HIS ARG ASP LEU ARG ALA ALA SEQRES 12 A 277 ASN ILE LEU VAL SER ASP THR LEU SER CYS LYS ILE ALA SEQRES 13 A 277 ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP ASN GLU TYR SEQRES 14 A 277 THR ALA ARG GLU GLY ALA LYS PHE PRO ILE LYS TRP THR SEQRES 15 A 277 ALA PRO GLU ALA ILE ASN TYR GLY THR PHE THR ILE LYS SEQRES 16 A 277 SER ASP VAL TRP SER PHE GLY ILE LEU LEU THR GLU ILE SEQRES 17 A 277 VAL THR HIS GLY ARG ILE PRO TYR PRO GLY MET THR ASN SEQRES 18 A 277 PRO GLU VAL ILE GLN ASN LEU GLU ARG GLY TYR ARG MET SEQRES 19 A 277 VAL ARG PRO ASP ASN CYS PRO GLU GLU LEU TYR GLN LEU SEQRES 20 A 277 MET ARG LEU CYS TRP LYS GLU ARG PRO GLU ASP ARG PRO SEQRES 21 A 277 THR PHE ASP TYR LEU ARG SER VAL LEU GLU ASP PHE PHE SEQRES 22 A 277 THR ALA THR GLU SEQRES 1 B 277 THR GLN LYS PRO GLN LYS PRO TRP TRP GLU ASP GLU TRP SEQRES 2 B 277 GLU VAL PRO ARG GLU THR LEU LYS LEU VAL GLU ARG LEU SEQRES 3 B 277 GLY ALA GLY GLN PHE GLY GLU VAL TRP MET GLY TYR TYR SEQRES 4 B 277 ASN GLY HIS THR LYS VAL ALA VAL LYS SER LEU LYS GLN SEQRES 5 B 277 GLY SER MET SER PRO ASP ALA PHE LEU ALA GLU ALA ASN SEQRES 6 B 277 LEU MET LYS GLN LEU GLN HIS GLN ARG LEU VAL ARG LEU SEQRES 7 B 277 TYR ALA VAL VAL THR GLN GLU PRO ILE TYR ILE ILE THR SEQRES 8 B 277 GLU TYR MET GLU ASN GLY SER LEU VAL ASP PHE LEU LYS SEQRES 9 B 277 THR PRO SER GLY ILE LYS LEU THR ILE ASN LYS LEU LEU SEQRES 10 B 277 ASP MET ALA ALA GLN ILE ALA GLU GLY MET ALA PHE ILE SEQRES 11 B 277 GLU GLU ARG ASN TYR ILE HIS ARG ASP LEU ARG ALA ALA SEQRES 12 B 277 ASN ILE LEU VAL SER ASP THR LEU SER CYS LYS ILE ALA SEQRES 13 B 277 ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP ASN GLU TYR SEQRES 14 B 277 THR ALA ARG GLU GLY ALA LYS PHE PRO ILE LYS TRP THR SEQRES 15 B 277 ALA PRO GLU ALA ILE ASN TYR GLY THR PHE THR ILE LYS SEQRES 16 B 277 SER ASP VAL TRP SER PHE GLY ILE LEU LEU THR GLU ILE SEQRES 17 B 277 VAL THR HIS GLY ARG ILE PRO TYR PRO GLY MET THR ASN SEQRES 18 B 277 PRO GLU VAL ILE GLN ASN LEU GLU ARG GLY TYR ARG MET SEQRES 19 B 277 VAL ARG PRO ASP ASN CYS PRO GLU GLU LEU TYR GLN LEU SEQRES 20 B 277 MET ARG LEU CYS TRP LYS GLU ARG PRO GLU ASP ARG PRO SEQRES 21 B 277 THR PHE ASP TYR LEU ARG SER VAL LEU GLU ASP PHE PHE SEQRES 22 B 277 THR ALA THR GLU HET 242 A 503 31 HET 242 B 503 31 HETNAM 242 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3- HETNAM 2 242 (TRIFLUOROMETHYL)PHENYL]BENZAMIDE HETSYN 242 AMINOQUINAZOLINE 1 FORMUL 3 242 2(C23 H17 F3 N4 O) FORMUL 5 HOH *271(H2 O) HELIX 1 1 PRO A 241 GLU A 243 5 3 HELIX 2 2 LEU A 286 LEU A 295 1 10 HELIX 3 3 SER A 323 LYS A 329 1 7 HELIX 4 4 THR A 330 LYS A 335 1 6 HELIX 5 5 THR A 337 ARG A 358 1 22 HELIX 6 6 ARG A 366 ALA A 368 5 3 HELIX 7 7 ALA A 408 GLY A 415 1 8 HELIX 8 8 THR A 418 THR A 435 1 18 HELIX 9 9 THR A 445 GLU A 454 1 10 HELIX 10 10 PRO A 466 TRP A 477 1 12 HELIX 11 11 ARG A 480 ARG A 484 5 5 HELIX 12 12 THR A 486 ASP A 496 1 11 HELIX 13 13 PRO B 241 GLU B 243 5 3 HELIX 14 14 PHE B 285 LEU B 295 1 11 HELIX 15 15 SER B 323 LEU B 328 1 6 HELIX 16 16 THR B 337 ARG B 358 1 22 HELIX 17 17 ARG B 366 ALA B 368 5 3 HELIX 18 18 PRO B 403 THR B 407 5 5 HELIX 19 19 ALA B 408 GLY B 415 1 8 HELIX 20 20 THR B 418 VAL B 434 1 17 HELIX 21 21 PRO B 466 TRP B 477 1 12 HELIX 22 22 ARG B 480 ARG B 484 5 5 HELIX 23 23 THR B 486 ASP B 496 1 11 SHEET 1 A 5 LEU A 245 GLY A 254 0 SHEET 2 A 5 GLY A 257 TYR A 264 -1 O VAL A 259 N LEU A 251 SHEET 3 A 5 THR A 268 LEU A 275 -1 O VAL A 272 N TRP A 260 SHEET 4 A 5 ILE A 312 THR A 316 -1 O ILE A 312 N LEU A 275 SHEET 5 A 5 LEU A 303 VAL A 307 -1 N TYR A 304 O ILE A 315 SHEET 1 B 2 ILE A 370 VAL A 372 0 SHEET 2 B 2 CYS A 378 ILE A 380 -1 O LYS A 379 N LEU A 371 SHEET 1 C 5 LEU B 245 GLY B 254 0 SHEET 2 C 5 GLY B 257 TYR B 264 -1 O VAL B 259 N LEU B 251 SHEET 3 C 5 THR B 268 LEU B 275 -1 O VAL B 272 N TRP B 260 SHEET 4 C 5 ILE B 312 THR B 316 -1 O ILE B 314 N LYS B 273 SHEET 5 C 5 LEU B 303 VAL B 307 -1 N ALA B 305 O ILE B 315 SHEET 1 D 2 ILE B 370 VAL B 372 0 SHEET 2 D 2 CYS B 378 ILE B 380 -1 O LYS B 379 N LEU B 371 CISPEP 1 GLU A 310 PRO A 311 0 -0.92 CISPEP 2 GLU B 310 PRO B 311 0 0.31 SITE 1 AC1 20 VAL A 259 ALA A 271 VAL A 272 LYS A 273 SITE 2 AC1 20 GLU A 288 MET A 292 LEU A 295 LEU A 300 SITE 3 AC1 20 VAL A 301 ILE A 314 THR A 316 GLU A 317 SITE 4 AC1 20 TYR A 318 MET A 319 HIS A 362 ILE A 380 SITE 5 AC1 20 ALA A 381 ASP A 382 PHE A 383 HOH A 630 SITE 1 AC2 21 VAL B 259 ALA B 271 LYS B 273 GLU B 288 SITE 2 AC2 21 MET B 292 LEU B 300 VAL B 301 ILE B 314 SITE 3 AC2 21 THR B 316 GLU B 317 TYR B 318 MET B 319 SITE 4 AC2 21 GLY B 322 TYR B 360 LEU B 371 ILE B 380 SITE 5 AC2 21 ALA B 381 ASP B 382 PHE B 383 ILE B 389 SITE 6 AC2 21 HOH B 518 CRYST1 142.660 66.890 78.510 90.00 112.00 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007010 0.000000 0.002832 0.00000 SCALE2 0.000000 0.014950 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013738 0.00000 MASTER 380 0 2 23 14 0 11 6 0 0 0 44 END